title: [Acute bacterial parotitis in infants under 3 months of age: a retrospective study in a pediatric tertiary care center].
abstract: BACKGROUND
  Acute bacterial parotitis is a rare infectious disease in infants under 3 months of age.
  
  
  OBJECTIVE
  To describe the clinical characteristics and the course of acute bacterial parotitis in infants less than 3 months old.
  
  
  METHODS
  Infants under 3 months of age, hospitalized at Robert Debré university hospital, Paris, France, between January 2005 and December 2009 for acute bacterial parotitis, were included in a retrospective study.
  
  
  RESULTS
  Five infants less than 3 months of age were included in this study, for a frequency of 2.5/1000 hospitalizations in this age group. All were born at term, 4 of 5 were male. Three of the 5 patients had specific clinical signs of parotitis on admission. One patient had septic shock on admission. The ultrasound confirmed the parotitis in all cases. No parotid abscess was demonstrated on imaging. All patients had at least one abnormal inflammatory biological test (WBC, CRP, PCT). Bacteria were identified in 4 of 5 cases: Staphylococcus aureus was isolated in the pus culture of the Stenon duct in 2 patients and a group B Streptococcus was isolated from blood culture of 2 other patients. The duration of intravenous antibiotic therapy varied from 4 to 13 days, and the total duration of antibiotic therapy was between 10 and 16 days. No surgical procedures were needed.
  
  
  CONCLUSIONS
  Acute bacterial parotitis in infants under 3 months of age might be associated with localized infections due to S. aureus, but also with a more severe clinical presentation due to group B streptococcus infection. Early diagnosis and appropriate antibiotic therapy might prevent the progression to serious complications.
authors: Service pédiatrie générale, pôle de pédiatrie aiguë et médecine interne, hôpital Robert Debré, Paris, France.
authors: J
authors: J
authors: Makhoul
authors: M
authors: M
authors: Lorrot
authors: N
authors: N
authors: Teissier
authors: G
authors: G
authors: Delacroix
authors: C
authors: C
authors: Doit
authors: E
authors: E
authors: Bingen
authors: A
authors: A
authors: Faye
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005260:Female; D006776:Hospitals, Pediatric; D006785:Hospitals, University; D006801:Humans; D007223:Infant; D008297:Male; D010309:Parotitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000302:isolation & purification*; D013290:Streptococcal Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013292:Streptococcus agalactiae / Q000302:isolation & purification*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin